Nluc Reporter Cell Line - MOLM-13

MOLM-13 is a widely recognized human acute myeloid leukemia (AML) cell line, originally established from the peripheral blood of a 20-year-old male patient during relapse of acute monocytic leukemia (FAB M5a). Growing in suspension, this cell line is particularly significant in oncological research because it harbors both the MLL-AF9 fusion gene and the internal tandem duplication of the FLT3 gene (FLT3-ITD), two genetic hallmarks associated with aggressive leukemia and poor clinical prognoses. The Nluc Reporter Cell Line - MOLM-13 enhances this foundational model through the stable integration of the NanoLuc (Nluc) reporter gene. NanoLuc is an engineered, exceptionally small (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When paired with its specific substrate, furimazine, it generates a luminescent signal up to 100-fold brighter than traditional firefly luciferase. Importantly, the engineered MOLM-13 Nluc cells maintain the exact morphological traits, suspension growth patterns, and critical mutational profile of the parental line, providing a highly reliable model for investigating molecular mechanisms of leukemia.

The exceptional brightness and enhanced stability of the Nluc-MOLM-13 cell line make it an indispensable asset for both early-stage in vitro assays and complex preclinical animal modeling. On the benchtop, the robust luminescence allows researchers to detect even minute cell populations, making it an ideal platform for high-throughput screening of novel targeted therapies, such as FLT3 inhibitors, and for conducting highly sensitive cytotoxicity and cell viability assays. The intense signal-to-noise ratio is especially useful for modeling minimal residual disease (MRD) in vitro. In vivo, this cell line is uniquely suited for studying systemic hematological malignancies. Because AML is a "liquid tumor," MOLM-13 cells are typically administered intravenously into immunodeficient mice, where they systemically disseminate and engraft in the bone marrow, spleen, and peripheral blood. The brilliant NanoLuc signal enables highly sensitive, non-invasive bioluminescence imaging (BLI) in living subjects, allowing researchers to accurately map leukemia progression, track metastatic dissemination, and longitudinally evaluate the therapeutic efficacy of experimental treatments, such as novel CAR-T cell therapies or small molecule drugs, without relying on survival endpoints alone.